Alnylam Pharmaceuticals (ALNY) Revenue (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Revenue for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 66.86% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2026 stood at $4.8 billion (up 153.15% YoY), and the FY2025 full-year result was $3.7 billion, up 65.19% from the prior year.
• Revenue improved to $1.3 billion in Q2 2026 per ALNY's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Revenue topped out at $1.3 billion in Q2 2026 and bottomed at $30.0 million in Q1 2025.
• Historically, Revenue has averaged $595.7 million across 5 years, with a median of $497.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Revenue sank 93.93% in 2025, then soared 3790.58% in 2026.
• Over 5 years, Revenue stood at $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then soared by 34.9% to $593.2 million in 2024, then jumped by 84.95% to $1.1 billion in 2025, then rose by 17.68% to $1.3 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $1.3 billion, $1.2 billion, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.